Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Minerva Neurosciences (NERV) Enterprise Value (2016 - 2026)

Minerva Neurosciences filings provide 3 years of Enterprise Value readings, the most recent being -$54.1 million for Q4 2021.

  • On a quarterly basis, Enterprise Value fell 112.53% to -$54.1 million in Q4 2021 year-over-year; TTM through Dec 2021 was -$54.1 million, a 112.53% decrease, with the full-year FY2021 number at -$54.1 million, down 112.53% from a year prior.
  • Enterprise Value hit -$54.1 million in Q4 2021 for Minerva Neurosciences, up from -$65.7 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$25.5 million in Q4 2020 to a low of -$80.2 million in Q1 2021.
  • Median Enterprise Value over the past 3 years was -$45.9 million (2019), compared with a mean of -$49.0 million.
  • Biggest five-year swings in Enterprise Value: skyrocketed 44.48% in 2020 and later plummeted 166.26% in 2021.
  • Minerva Neurosciences' Enterprise Value stood at -$45.9 million in 2019, then soared by 44.48% to -$25.5 million in 2020, then plummeted by 112.53% to -$54.1 million in 2021.
  • The last three reported values for Enterprise Value were -$54.1 million (Q4 2021), -$65.7 million (Q3 2021), and -$74.3 million (Q2 2021) per Business Quant data.